A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 55-60

  Viswanathan, Akila N ^a   Lee, Hang ^b   Berkowitz, Ross ^a   Berlin, Suzanne ^c   Campos, Susanna ^c   Feltmate, Colleen ^a   Horowitz, Neil ^a   Muto, Michael ^a   Sadow, Cheryl A ^a   Matulonis, Ursula ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bevacizumab; Gynecologic malignancies; Radiation

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; HEPARIN; OXALIPLATIN; PACLITAXEL;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; BONE MARROW DISEASE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOSIS; CARCINOSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; EPISTAXIS; EXTERNAL BEAM RADIOTHERAPY; EYE DISEASE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; METABOLIC DISORDER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVARY CANCER; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; RADIATION DOSE DISTRIBUTION; SKIN DISEASE; SOFT TISSUE DISEASE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VERY ELDERLY;

BEVACIZUMAB; GYNECOLOGIC MALIGNANCIES; RADIATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84892732712     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.10.031     Document Type: Article

References (21)

1. C.L. Creutzberg, R.A. Nout, M.L. Lybeert, C.C. Warlam-Rodenhuis, J.J. Jobsen, and J.M. Mens et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma Int J Radiat Oncol Biol Phys 81 2011 e631 e638
2. J.D. Sears, K.M. Greven, H.M. Hoen, and M.E. Randall Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer Cancer 74 1994 1303 1308
3. K.V. Albuquerque, R. Singla, R.K. Potkul, D.M. Smith, S. Creech, and S. Lo et al. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer Gynecol Oncol 96 2005 701 704
4. A. Mazurek, P. Pierzynski, P. Kuc, P. Kopinski, S. Terlikowski, and W. Niklinska et al. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer Neoplasma 51 2004 193 197
5. R.J. Gornall, F.W. Anthony, E.J. Coombes, P. Hogston, and R.P. Woolas Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement Int J Gynecol Cancer 11 2001 164 166
6. A. Mazurek, P. Kuc, S. Terlikowski, and T. Laudanski Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer Neoplasma 53 2006 242 246
7. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak, D.P. Calvin, H.J. Mauceri, and R.M. Salloum et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
8. C.G. Lee, M. Heijn, E. di Tomaso, G. Griffon-Etienne, M. Ancukiewicz, and C. Koike et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
9. S. Bao, Q. Wu, S. Sathornsumetee, Y. Hao, Z. Li, and A.B. Hjelmeland et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 2006 7843 7848
10. M.C. Wergin, M. Roos, N. Inteeworn, D. Laluhova, K. Allemann, and B. Kaser-Hotz The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome Radiother Oncol 79 2006 239 244
11. C.G. Willett, Y. Boucher, E. di Tomaso, D.G. Duda, L.L. Munn, and R.T. Tong et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
12. T.E. Schefter, K. Winter, J.S. Kwon, K. Stuhr, K. Balaraj, and B.P. Yaremko et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417 Int J Radiat Oncol Biol Phys 83 2012 1179 1184
13. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 2011 2259 2265
14. J.D. Wright, M.A. Powell, J.S. Rader, D.G. Mutch, and R.K. Gibb Bevacizumab therapy in patients with recurrent uterine neoplasms Anticancer Res 27 2007 3525 3528
15. G.A. McCann, B. Smith, F.J. Backes, K. Rath, S. Chacko, and R. Salani et al. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol 127 2012 362 366
16. W. Small Jr., L.K. Mell, P. Anderson, C. Creutzberg, J. De Los Santos, and D. Gaffney et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer Int J Radiat Oncol Biol Phys 71 2008 428 434
17. P.D. Poorvu, C.A. Sadow, K. Townamchai, A.L. Damato, and A.N. Viswanathan Int J Radiat Oncol Biol Phys Duodenal and Other Gastrointestinal Toxicity in Cervical and Endometrial Cancer Treated With Extended-Field Intensity Modulated Radiation Therapy to Paraaortic Lymph Nodes 85 5 2013 1262 1268
18. K. Townamchai, P. Poorvu, A.L. Damato, R. DeMaria, L.J. Lee, and S. Berlin et al. Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer Pract Radiat Oncol Epub 1 2013 1 2
19. C.L. Creutzberg, W.L. van Putten, P.C. Koper, M.L. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial Gynecol Oncol 89 2003 201 209
20. A. Jhingran, T.W. Burke, and P.J. Eifel Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy Int J Radiat Oncol Biol Phys 56 2003 1366 1372
21. L.J. Lee, A.L. Damato, and A.N. Viswanathan Clinical outcomes following 3D image-guided brachytherapy for vaginal recurrence of endometrial cancer Gynecol Oncol Epub 2013